Dr. Ahmed Bouzidi
- Founder & CEO, Vaxeal
Ahmed Bouzidi, Ph.D, is the founder and CEO of Vaxeal. The company is today at the forefront of cancer immunotherapy research and innovation. He previously founded and managed SEDAC- Therapeutics inc., a leading biotech pioneer in peptide-based therapeutic vaccines (exit by Leveraged Buy Out), and Biophysiomics inc., a pioneer in proteomics (acquired by Kuachang Science & Technology, China).
Ahmed is a board member of Vaccines Europe and of the European Biopharmaceutical Enterprises (EBE-biopharma), and is a Senior Associate of the Royal Society of Medicine. He held previously senior advisory positions with Chinese pharmaceutical companies and public institutions, and worked 10 years as senior researcher at the LFB.
He holds a Master degree in Animal Biology (University of Lille, France), a PhD in Cellular Biology, and a MBA (University of New Hampshire, USA).